The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNetscientific Regulatory News (NSCI)

Share Price Information for Netscientific (NSCI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 63.50
Bid: 62.00
Ask: 65.00
Change: 1.00 (1.60%)
Spread: 3.00 (4.839%)
Open: 62.50
High: 63.50
Low: 62.50
Prev. Close: 62.50
NSCI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Ventive secures c.£900,000 investment

6 Nov 2023 07:00

RNS Number : 4115S
NetScientific PLC
06 November 2023
 

For release: 07.00, 6 November 2023

 

 

 

 

NetScientific plc

("NetScientific" or the "Company")

 

Heat pump specialist Ventive secures c.£900,000 investment

NetScientific Plc (AIM: NSCI), the deep tech and life sciences VC investment group, announces that its portfolio company Ventive has successfully closed a c.£900,000 investment ("Investment").

The Investment included £316,000 from existing shareholders and the conversion of two existing convertible loans (and interest thereon) valued at c.£600,000. This is the first closing as part of Ventive's proposed £1 million to £1.5 million investment programme, with further new investment anticipated prior to 30 April 2024 in one or more additional closings.

This additional funding is complemented by ongoing non-dilutive funding from, amongst other grants awarded, a £1.5 million BEIS grant secured in 2022, as well as a recently awarded £100,000 UK Government grant focused on 'net zero HVAC' systems.

The Investment was led and syndicated by EMV Capital, the Company's wholly owned venture capital and corporate finance firm. It follows the initial investment led and syndicated by EMV Capital that was announced (via RNS Reach) on 20 October 2022, where EMV Capital secured an initial c.16% stake in partial settlement of its fees. Since that initial investment, the value creation team of EMV Capital has worked closely with Ventive to stabilise and develop its business plan and product range.

The proceeds of the Investment will support the completion of the design and test phase and factory build for Ventive's modular heat pumps, further enhancements to its passive air ventilation product range, and build-up of its marketing and sales capacity to drive sales of its existing product range. The Ventive balance sheet is also streamlined following the conversion of the convertible loans.

Following completion of the Investment, the total equity holding of the NetScientific group in Ventive is 11.0% on a fully diluted basis, which includes the partial settlement of its corporate finance fees relating to the Investment. This holding equates to a post-investment fair value of £893,000, a substantial increase of 1,617% from the £52,000 reported as at 31 December 2022. In addition, following the introduction of investors to Ventive by EMV Capital under its capital efficient model, NetScientific's capital under advisory with Ventive is now 23.8% of the fully diluted share capital. 

Ventive designs and manufactures intelligent heating and ventilation solutions to make buildings healthy, comfortable, efficient, and affordable. Its products address two high priority markets segments: air quality and sustainable heating.

Ventive's passive air ventilation system has been delivered to over 30 schools and five leisure centres, achieving excellent air quality results. Its novel heat pump product, which is in advanced stages of development, is a comprehensive solution for residential applications, with a unique modular design and a novel thermal store. Momentum for the business is underpinned by significant regulatory changes, increasing energy prices, and climate change policies.

Rob Morrison, Managing Director of Ventive, said:

"This investment is a strong endorsement of our work, and recognition of Ventive as a pioneer in the design of naturally intelligent ventilation systems to deliver fresh air at minimal energy cost. Since heat pumps are powered by electricity, a comparatively easy source of energy to decarbonise, they can play a prominent role in bringing down the environmental footprint of homes and other buildings.

"EMV Capital has provided invaluable support to our fundraising efforts and growth strategy planning, and we are grateful to our shareholders for their continued support in a tough macro-economic climate."

Ed Hooper, Executive Director of NetScientific and Investment Director at Ventive, added:

"We are pleased to see Ventive close out the first tranche of this important fundraising programme, which includes both fresh investment and the conversion of existing convertible loans. This transaction again demonstrates the strength of our capital efficient investment model and the successful execution of our strategy to increase the net asset value and fair value of our business by progressing cohort portfolio companies through value creation stages, obtaining third party investment, and providing proactive portfolio management.

"We believe that this fundraising positions Ventive well for further growth and we look forward to continuing to work closely with Ventive in this rapidly growing high-impact market segment."

 

 

The person responsible for arranging the release of this announcement on behalf of the Company is Edward Hooper, General Counsel and Executive Director of the Company.

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE UK VERSION OF REGULATION (EU) NO 596/2014 WHICH IS PART OF UK LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

-Ends-

For more information, please contact:

NetScientific

Ilian Iliev, CEO

Via Belvedere Communications

 

Panmure Gordon (UK) Limited (NOMAD and Broker)

 

Emma Earl / Freddy Crossley / Mark Rogers (Corporate Finance)

Rupert Dearden (Corporate Broking)

+44 (0)20 7886 2500

Belvedere Communications

John West / Llew Angus / Lily Pearce

 

+44 (0)20 7653 8702

 

About NetScientific

NetScientific plc (AIM: NSCI) is a deep tech and life sciences VC investment group with an international portfolio of innovative companies.

NetScientific identifies, invests in, and builds high growth companies in the UK and internationally. The company adds value through the proactive management of its portfolio, progressing to key value inflection points, and delivering investment returns through partial or full liquidity events.

NetScientific differentiates itself by employing a capital-light investment approach, making judicial use of its balance sheet and syndicating investments through its wholly owned VC subsidiary, EMV Capital. The group secures a mixture of direct equity stakes and carried interest stakes in its portfolio of companies, creating a lean structure that can support a large portfolio.

NetScientific is headquartered in London, United Kingdom, and is admitted to trading on AIM, a market operated by the London Stock Exchange.

www.netscientific.net

About Ventive

Ventive designs and manufactures innovative intelligent building service systems in the UK, with an aim to create comfort without costing the Earth. From ventilation to heating and cooling, its ambitious team has already commercialised a few technologies and is well positioned to address the complexities of the Energy Transition with its new range of all-in-one home energy systems. Ventive has the ambition to provide a healthy, comfortable and safe indoor environment intelligently and at a reasonable cost, also opening the opportunity to help demand for energy management on an aggregated scale.

Ventive was founded by serial entrepreneur and architect Tom Lipinski with a vision to improve the comfort and sustainability of residential built environment.

https://ventive.co.uk/

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FURFLFEFLELEIIV
Date   Source Headline
14th Nov 20222:05 pmRNSSecond Price Monitoring Extn
14th Nov 20222:00 pmRNSPrice Monitoring Extension
9th Nov 20227:00 amRNSBoard Change
7th Nov 20223:40 pmRNSPDS reports presentation of data at cancer society
20th Oct 20227:00 amRNSEMV Capital secures investment in Ventive
11th Oct 20224:00 pmRNSPDS Update
3rd Oct 20221:56 pmRNSPDS completes End-of-Phase 2 meeting with FDA
30th Sep 20227:00 amRNSHalf-year Report
25th Aug 20227:00 amRNSPDS Completes $35 Million Financing Agreement
16th Aug 20227:00 amRNSAcquisition of 30% Vortex stake & new Vortex CEO
8th Aug 20224:45 pmRNSPDS Reports Q2 2022 Results & Business Update
29th Jun 20222:05 pmRNSResult of AGM
28th Jun 20229:15 amRNSHolding(s) in Company
27th Jun 20228:30 amRNSDirector/PDMR Shareholding
27th Jun 20228:30 amRNSHolding(s) in Company
22nd Jun 20227:00 amRNSResult of Placing and Total Voting Rights
21st Jun 20224:41 pmRNSProposed Placing to raise at least £1.5 million
17th Jun 202212:00 pmRNSNetScientific to increase Q-Bot stake to 23.7%
15th Jun 20227:00 amRNSQ-Bot secures £1.6m of investment to fund growth
7th Jun 202211:07 amRNSNotice of AGM and Annual Report & Accounts
6th Jun 20227:00 amRNSPDS Granted FDA Fast Track Designation for PDS0101
27th May 20222:39 pmRNSPDS Biotech - new data for ongoing clinical trials
19th May 20227:00 amRNSGeneral Counsel Strategic Hire & Grant of Options
16th May 20227:00 amRNSProAxsis Update
12th May 20227:00 amRNSFinal Results
11th May 20223:46 pmRNSPDS Reports Q1 2022 Results & Business Update
9th May 20227:00 amRNSNotice of Results & Investor Presentation
6th May 20227:00 amRNSAcquisition of 30% of Vortex Biotech Holdings
25th Apr 20222:05 pmRNSSecond Price Monitoring Extn
25th Apr 20222:00 pmRNSPrice Monitoring Extension
25th Apr 202211:05 amRNSSecond Price Monitoring Extn
25th Apr 202211:00 amRNSPrice Monitoring Extension
31st Mar 20221:24 pmRNSPDS Provides Business Update & Full-Year Results
4th Mar 20227:30 amRNSPublication of Shareholder Newsletter
24th Feb 20224:45 pmRNSPDS Announces Preliminary Safety Data on PDS0101
15th Feb 20222:32 pmRNSPDS Clinical Trial with Mayo Clinic
2nd Feb 20223:00 pmRNSPDS Phase 2 Trial Update
28th Jan 20228:45 amRNSPDS Announces Preclinical Data for PDS0202 Vaccine
18th Jan 20227:00 amRNSHolding(s) in Company
10th Jan 20222:20 pmRNSPDS Granted Novel HPV16 Immunotherapy Patent
10th Jan 20227:00 amRNSProAxsis CEO End of Year Update
29th Dec 20218:47 amRNSIssue of Equity
21st Dec 20211:59 pmRNSTR-1: Form for notification of major holdings
21st Dec 20217:00 amRNSQ-Bot Investment and Share Acquisition
20th Dec 20217:00 amRNSAcquisition of majority stake in Cetromed
13th Dec 20217:00 amRNSMartlet Capital Update
6th Dec 20212:53 pmRNSPDS Phase 2 Clinical Trial Update
26th Nov 20217:00 amRNS$1million investment in portfolio company, EpiBone
10th Nov 20211:58 pmRNSPDS Reports Q3 2021 Results & Business Update
4th Nov 20217:00 amRNSSofant Signs EUR7.3m ESA Contract

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.